A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as Firt-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trail)

  • Rinehart, John (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/072/28/10